Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Locked Nucleic Acid Holds Promise in the Treatment of Cancer

Author(s): Miriam Frieden and Henrik Orum

Volume 14 , Issue 11 , 2008

Page: [1138 - 1142] Pages: 5

DOI: 10.2174/138161208784246234

Price: $65

Abstract

Providing novel treatments to help cancer patients live longer and have better lives remains one of the biggest challenges of the pharmaceutical industry. Today much is known about the molecular and genetic causes of cancers thus facilitating the development of novel targeted cancer drugs with improved risk-benefit ratios compared to contemporary broadly-acting, cytotoxic cancer drugs. Antisense therapy, e.g. the use of single stranded oligonucleotides as therapeutic modalities, provides the means to develop such targeted drugs, and in recent years this concept has enjoyed a major renaissance. Locked Nucleic Acid (LNA) is a novel, third generation RNA analogue that displays most if not all of the characteristics required to make potent and safe antisense drugs. Here we review the key properties of LNA oligonucleotides in the context of their use as safe and effective antisense drugs and provide a status on their therapeutic development in the field of cancer.

Keywords: Locked Nucleic Acid (LNA), RNA antagonists, cancer, siRNA, antisense, microRNA


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy